Biotech - Spark Newswire

1 minute read

Clene’s Amyotrophic Lateral Sclerosis Candidate Delays Disease Progression, New Data Shows

Today, 3:24 AM

Clene Inc (NASDAQ:CLNN) announced new results from exploratory analyses, including delayed time to key clinical progression events in amyotrophic lateral sclerosis…

CLNN

1 minute read

AstraZenceca’s Tagrisso Shows Survival Benefit In Early-Stage Lung Cancer Settings

By Vandana Singh

Today, 3:24 AM

AstraZeneca Plc (NASDAQ:AZN) released topline data from the ADAURA Phase 3 trial demonstrating Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement…

AZN

1 minute read

AstraZeneca’s Immunotherapy Imfinzi Shows Improvement In Survival Chances In Lung Cancer Patients

By Vandana Singh

Today, 3:24 AM

In a trial, lung cancer patients treated with AstraZeneca plc’s (NASDAQ:AZN) immunotherapy Imfinzi (durvalumab) pre- and post-surgery lived significantly longer without the…

AZN

1 minute read

The FDA has Cleared Vertex Pharmaceuticals’ Investigational New Drug Application For VX-264, Stem Cell-Derived Fully Differentiated Pancreatic Islet Cell Therapy Encapsulated Into Vertex-Developed, Immunoprotective Device For Type 1 Diabetes

By Benzinga Newsdesk

Today, 3:24 AM

Vertex plans to initiate a Phase 1/2 clinical trial in the first half of 2023 to study the safety, tolerability and efficacy of VX-264 in patients with T1D. The company previously received approval from Health Canada

VRTX

1 minute read

AstraZeneca Announces TAGRISSO Demonstrated Statistically And Clinically Meaningful Improvement In Overall Survival

By Benzinga Newsdesk

Today, 3:24 AM

Positive high-level results from the ADAURA Phase III trial showed AstraZeneca's TAGRISSO® (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in overall survival

AZN

5 minute read

Reported Late Wednesday March 08, Bionomics Reports Promising Full Results Analysis From PREVAIL Phase 2 Study Of BNC210 Social Anxiety Disorder; PREVAIL Did Not Meet Its Primary Endpoint

By Happy Mohamed

Today, 3:24 AM

Both doses of BNC210 as an acute treatment resulted in reductions in anxiety across multiple phases of the public speaking challenge Results achieved statistical significance in post-hoc analysis of the full

BNOX

3 minute read

Reported Late Wednesday March 08, ProMIS Neurosciences Announces FY22 Financial Results And Recent Highlights; Cash And Cash Equivalents Were $5.9M As Of December 31, 2022 Vs $16.9M YoY

By Happy Mohamed

Today, 3:24 AM

Completed all preclinical studies and manufacturing to support PMN310 IND submission to U.S. Food and Drug Administration Preclinical data that further characterize ongoing programs, including PMN310, to be presented

PMN

2 minute read

Florida Republicans Propose Six-Week Abortion Ban, Further Narrowing Abortion Access

By Vandana Singh

Today, 3:24 AM

Florida Republicans introduced a bill to ban abortion after six weeks of pregnancy, offering exemptions for victims of rape and incest cases.

WBA

2 minute read

Canadian Agency For Drugs And Technologies In Health Recommends Reimbursement For BioCryst’s ORLADEYO For The Routine Prevention Of Attacks In Hereditary Angioedema Patients In Canada

By Happy Mohamed

Today, 3:24 AM

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committee (CDEC) has issued a positive recommendation for

BCRX

1 minute read

CEL-SCI’s Lead Head & Neck Cancer Candidate Shows 43% Survival Extension

By Vandana Singh

Today, 3:24 AM

CEL-SCI Corporation (NASDAQ:CVM) reported new data from its pivotal Phase 3 study of Multikine (Leukocyte Interleukin) in newly diagnosed locally advanced…

CVM